Clinical Trials
29 trialsNCT07100080 2026-05-27
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07005102 2026-05-22
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
AbbVie
Phase 2/3 Recruiting
NCT07365319 2026-05-20
TeLuRide-008
Eikon Therapeutics
Phase 2/3 Recruiting
NCT07063745 2026-05-18
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07129993 2026-05-14
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
Phase 2/3 Recruiting
NCT07106762 2026-05-12
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT04442022 2026-05-06
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Karyopharm Therapeutics Inc
Phase 2/3 Active not recruiting
NCT07554456 2026-04-28
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT05893888 2026-04-23
A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
Privo Technologies
Phase 2/3 Recruiting
NCT03178552 2026-03-09
B-FAST
Hoffmann-La Roche
Phase 2/3 Active not recruiting
NCT06236438 2026-02-23
LIVIGNO-4
AbbVie
Phase 2/3 Recruiting
NCT04619797 2026-02-03
SKYSCRAPER-06
Hoffmann-La Roche
Phase 2/3 Completed
NCT05800015 2026-01-22
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT07332533 2026-01-12
A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer
Shanghai JMT-Bio Inc.
Phase 2/3 Not yet recruiting
NCT06493552 2025-04-03
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
Phase 2/3 Recruiting
NCT01249352 2025-03-31
NICE
Eurofarma Laboratorios S.A.
Phase 2/3 Completed
NCT06123884 2025-02-10
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Bio-Thera Solutions
Phase 2/3 Recruiting
NCT06755515 2025-01-01
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3 Enrolling by invitation
NCT04864782 2024-01-12
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Terminated
NCT05576272 2023-11-22
A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Unknown
NCT04066491 2023-11-14
Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC
EMD Serono
Phase 2/3 Terminated
NCT02709512 2023-10-04
ATOMIC
Polaris Group
Phase 2/3 Completed
NCT03086993 2022-03-24
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma
Delcath Systems Inc.
Phase 2/3 Unknown
NCT04750083 2021-02-11
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 2/3 Unknown
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated
NCT01383148 2017-01-05
TIME
Transgene
Phase 2/3 Terminated
NCT00261703 2012-05-11
Docetaxel in Head and Neck Cancer
Sanofi
Phase 2/3 Completed
NCT00401323 2011-01-20
Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Sanofi
Phase 2/3 Completed
NCT00337532 2010-02-04
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer
Bristol-Myers Squibb
Phase 2/3 Completed